Skip to main content
SpringerLink
Log in
Book cover

Endocrine Surgery in Children pp 107–120Cite as

Neuroblastoma

  • Chapter
  • First Online:

  • 1256 Accesses

Abstract

Neuroblastoma represents 10% of childhood solid tumours, with an incidence of 6–8 per million. The tumours develop in cells derived from the neural crest and may arise in any structure with the crest as its origin. There is an extra-ordinary variation in the presentation and outcome of the disease with some patients dying from extensive metastases in spite of intensive multimodal therapy and others experiencing disappearance of the tumour with no treatment.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Willis RA. Pathology of tumours. 4th ed. London: Butterworth& Co; 1967. pp. 857–60.

    Google Scholar 

  2. Pepper W. A study of congenital sarcoma of the liver and suprarenal. Am J Med Sci. 1901;121:287–99.

    Article  Google Scholar 

  3. Wright JH. Neurocytoma or neuroblastoma, a kind of tumour not generally recognised. J Exp Med. 1910;12:556–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lehman EP. Adrenal neuroblastoma in infancy—15 year survival. Ann Surg. 1932;95:473.

    Google Scholar 

  5. Blacklock JWS. Neurogenic tumours of the sympathetic system in children. J Pathol Bacteriol. 1934;39:27–48.

    Article  Google Scholar 

  6. Wittenborg MH. Roentgen therapy in neuroblastoma. A review of 73 cases. 1950; 54:679–88.

    Google Scholar 

  7. Gross RE, Farber S, Martin LW. Neuroblastoma sympatheticum: a study and report of 217 cases. Pediatrics. 1959;23:1179–91.

    CAS  PubMed  Google Scholar 

  8. Koop CE, Johnson DG. Neuroblastoma: an assessment of therapy in reference to staging. J Ped Surg. 1971;6:595–600.

    Article  CAS  Google Scholar 

  9. Swank RL II, Fetterman GH, Sieber WK, Kiesewetter WB. Prognostic factors in neuroblastoma. Ann Surg. 1971;174:428–35.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lehman EP. Neuroblastoma. With report of a case. J Med Res. 1917; 36:309–26.

    Google Scholar 

  11. Sutow WW, Gehan EA, Heyn RM, et al. Comparison of survival curves, 1956 versus 1962, in children with Wilms’ tumour and neuroblastoma. Pediatrics. 1970;45:800–11.

    CAS  PubMed  Google Scholar 

  12. Pinkel D, Pratt C, Holton C, et al. Survival of children with neuroblastoma treated with combination chemotherapy. J Pediatr. 1968;73:928–31.

    Article  CAS  PubMed  Google Scholar 

  13. Leikin S, Evans A, Heyn R, Newton W. The impact of chemotherapy on advanced neuroblastoma: survival of patients diagnosed in 1956, 1962 and 1966–68 in Children’s Cancer Study Group A. J Pediatr. 1974;84:131–4.

    Article  CAS  PubMed  Google Scholar 

  14. Sieber WK, Dibbins AW, Wiener ES. In paediatric surgery. 3d ed. In: Ravitch MM, Welch KJ, Benson CD, Aberdeen E, Randolph JG, editors. Yearbook Medical Publishers Inc; 1979. Ch. 99, p. 1095.

    Google Scholar 

  15. Evans AE, D’Angio GJ, Randolph J. A proposed staging system for children with neuroblastoma. Cancer. 1971;27:374–8.

    Article  CAS  PubMed  Google Scholar 

  16. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971;31:2098–103.

    CAS  PubMed  Google Scholar 

  17. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874–81.

    Article  CAS  PubMed  Google Scholar 

  18. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466–77.

    Article  CAS  PubMed  Google Scholar 

  19. Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group classification system: an INRG task force report. J Clin Onc. 2009;27:289–97.

    Article  Google Scholar 

  20. Monclair T, Brodeur GM, Ambros PF, et al. The international Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27:298–303.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cecchetto G, Mosseri V, Bernardi B, et al. Surgical risk factors in primary surgery for localised neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Onc. 2005;23:8483–9.

    Article  Google Scholar 

  22. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, … Monclair T. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011; 261:243–57.

    Google Scholar 

  23. Beckwith JB, Martin RF. Observations on the histopathology of neuroblastomas. J Ped Surg. 1968;3:106–10.

    Article  CAS  Google Scholar 

  24. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastic tumours: definitions of subtypes of ganglioneuroblastomaand an age linked classification of neuroblastomas. J NatCancer Inst. 1984;73:405–16.

    CAS  Google Scholar 

  25. Joshi VV, Cantor Altshuler G, et al. Age linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer. 1992;69:2197–211.

    Article  CAS  PubMed  Google Scholar 

  26. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumours: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349–63.

    Article  CAS  PubMed  Google Scholar 

  27. Peuchmar M, d’Amore ES, Joshi VV, et al. Revision of the international neuroblastoma pathology classification: confirmation of the favourable and unfavourable diagnostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98:2274–81.

    Article  Google Scholar 

  28. Sano H, Bonadio J, Gerbing RB, et al. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. Eur J Cancer. 2006;42:1113–9.

    Article  PubMed  Google Scholar 

  29. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Eng J Med. 1984;311:231–5.

    Article  CAS  Google Scholar 

  30. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.

    Article  CAS  PubMed  Google Scholar 

  31. Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer. 1977;40:2256–63.

    Article  CAS  PubMed  Google Scholar 

  32. Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumours with increased risk for metastatic relapses in localised and 4S neuroblastoma. Clin Cancer Res. 2006;12:3368–73.

    Article  CAS  PubMed  Google Scholar 

  33. Bown N, Cotteril S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Eng J Med. 1999; 340:1954–61.

    Google Scholar 

  34. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971–4.

    Article  CAS  PubMed  Google Scholar 

  35. Stiller CA. Trends in neuroblastoma in Great Britain: incidence and mortality 1971–1990. Eur J Cancer. 1993;29A:1008–12.

    Article  CAS  PubMed  Google Scholar 

  36. Gutierrez JC, Fischer AC, Sola JE, Perez CA, Koniaris LG. Markedly improving survival of neuroblastoma: a 30 year analysis of 1646 patients. Ped Surg Int. 2007;23:637–46.

    Article  Google Scholar 

  37. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumours: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Nat Cancer Inst. 1984;73:405–16.

    Article  CAS  PubMed  Google Scholar 

  38. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage 3 neuroblastoma based on prospective biologic staging: a Children’s Cancer Group Study. J Clin Onc. 1998;16:1256–64.

    Article  CAS  Google Scholar 

  39. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II Neuroblastoma treated with surgery as primary therapy: a Children’s Cancer Group Study. J Clin Onc. 2000;18:18–26.

    Article  CAS  Google Scholar 

  40. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16.

    Article  CAS  PubMed  Google Scholar 

  41. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007; 369:2016–20.

    Google Scholar 

  42. O’Neill JA, Littman P, Blitzer P, Soper K, Chatten J, Shimada H. The role of surgery in localised neuroblastoma. J Ped Surg. 1985;20:708–12.

    Article  Google Scholar 

  43. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Onc. 1989;7:236–44.

    Article  CAS  Google Scholar 

  44. Evans AE, Silber JH, Shpilski A, D’Angio GJ. Successful management of low-stage Neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Onc. 1996;14:2504–10.

    Article  CAS  Google Scholar 

  45. Hero B, et al. Localised infant neuroblastomas often show spontaneous regression: results of the prospective trial NB95-S and NB97. J Clin Onc. 2008;26:1504–10.

    Article  Google Scholar 

  46. Rubie H, Hartman O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localised neuroblastoma: results of the French neuroblastoma 90 study. J Clin Onc. 1997;15:1171–82.

    Article  CAS  Google Scholar 

  47. Shamberger RC, Smith EI, Joshi W, et al. The risk of nephrectomy during local control in abdominal neuroblastoma. J Ped Surg. 1998;33:161–4.

    Article  CAS  Google Scholar 

  48. Kiely E. A technique for excision of abdominal neuroblastoma. Ann RCS Eng. 2007;89:342–8.

    Google Scholar 

  49. LaQuaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung N-KV. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Ped Surg. 1994;29:1162–6.

    Article  CAS  Google Scholar 

  50. Holmes K, et al. Advances in neuroblastoma research. Cologne: Plenary 12; 2014.

    Google Scholar 

  51. De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008;99:1027–33.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Kohler JA, Rubie H, Castel V, et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. Eur J Cancer. 2013;49(17):3671–9.

    Article  CAS  PubMed  Google Scholar 

  53. Haase GM, Wong KY, de Lorimer AA, Sather HN, Hammond GD. Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Ped Surg. 1989;24:194–200.

    Article  CAS  Google Scholar 

  54. Powis M, Imeson J, Holmes SJK. The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group. J Ped Surg. 1996;31:516–9.

    Article  CAS  Google Scholar 

  55. Modak S, Kushner, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer. 2009; 45:90–8.

    Google Scholar 

  56. Hero B, et al. Localised infant neuroblastomas often show spontaneous regression: results of the prospective trial NB95-S and NB97. J Clin Onc. 2008; 26(9):1504–10.

    Google Scholar 

  57. Park JR, Villablanca JG, London WB, et al. Outcome of high risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: A report from the Children’s Oncology Group. Ped Blood and Cancer. 2009;52:44–50.

    Article  Google Scholar 

  58. Ladenstein R, Valteau-Couanet D, Brock P, et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Onc. 2010; 28:3516–24.

    Google Scholar 

  59. Yu AL, Gilman, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma. NEng J Med. 2010; 363:1324–34.

    Google Scholar 

  60. Haase GM, O’Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor risk neuroblastoma. J Ped Surg. 1991; 26:1119–23.

    Google Scholar 

  61. Tsuchida Y, Yokoyam J, Kaneko M, et al. Therapeutic significance of surgery in advanced neuroblastoma: a report from the Study Group of Japan. J Ped Surg. 1992; 27:616–22.

    Google Scholar 

  62. Rich BS, McEvoy MP, LaQuaglia MP, Wolden SL. Local control, survival and operative morbidity and mortality after re-resection and intra-operative radiation therapy for recurrent or persistent primary high-risk neuroblastoma. J Ped Surg. 2011;46:97–102.

    Article  Google Scholar 

  63. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children’s Cancer Group Study. J Ped Surg. 2004;39:931–6.

    Article  Google Scholar 

  64. Kaneko M, Ohakawa H, Iwakawa M. Is extensive surgery required for treatment of advanced neuroblastoma? J Ped Surg. 1997;32:1616–9.

    Article  CAS  Google Scholar 

  65. Castel V, Tovar J, Costa J, et al. The role of surgery in stage IV neuroblastoma. J Ped Surg. 2002;37:1574–8.

    Article  Google Scholar 

  66. Berthold F, Trechow R, Utsch S, Zieschang J. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Ped Hemat Onc. 1992; 14:207–15.

    Google Scholar 

  67. Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials (1979–1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003; 197:11–17.

    Google Scholar 

  68. Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Surg. 2002;12:402–9.

    Article  Google Scholar 

  69. La Quaglia MP, Kushner BH, Su W, et al. The impact of gross total resection on local control and survival in high risk neuroblastoma. J Ped Surg. 2004; 39:412–7.

    Google Scholar 

  70. SimonT, Haberle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol. 2013; 31:752–8.

    Google Scholar 

  71. Schleiermacher G, Rubie H, Hartmann O, Bergeron C, Chastagner P, Medinaud F, Michon J. Treatment of stage 4s neuroblastoma—report of 10 years experience of French Society of Paediatric Oncology (SFOP). B J Cancer. 2003;89:470–6.

    Article  CAS  Google Scholar 

  72. Hsu LL, Evans AE, D’Angio GJ. Hepatomegaly in neuroblastoma stage 4S: criteria for treatment of the vulnerable neonate. Med Ped Onc. 1996; 27:521–8.

    Google Scholar 

  73. Simon T, Hero B, Bongartz R, Schmidt M, Muller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease. Strahlenther Onkol. 2006;182:389–94.

    Article  PubMed  Google Scholar 

  74. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high risk neuroblastoma: a Children’s Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28–39.

    Article  PubMed  Google Scholar 

  75. Voute PA, Hoefnagel CA, De KJ, Valdes OR, Bakker DJ, van de Kleij AJ. Results of treatment with 131 I-meta-iodobenzylguanidine (131I MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res. 1991; 366:439–45.

    Google Scholar 

  76. Tuchman M, Morris CL, Ramnaraine ML, Bowers LD, Krivit W. Value of random urinary homovanillic and vanillylmandelic acid levels in the management of patients with neuroblastoma: comparison with 24 h urine collections. Pediatrics. 1985;75:234–8.

    Google Scholar 

  77. Sawada T. Past and future of neuroblastoma screening in Japan. Am J Pediatr Hematol Oncol. 1992;14:320–6.

    Article  CAS  PubMed  Google Scholar 

  78. Ajiki W, Tsukuma H, Oshima A, Kawa K. Effects of mass screening for neuroblastoma on incidence, mortality and survival rates in Osaka, Japan. Cancer Causes Control. 1998;9:631–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Surgery, St. George’s Hospital, London, SW17 0QT, UK

    Keith Holmes

Authors
  1. Keith Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith Holmes .

Editor information

Editors and Affiliations

  1. Seattle Children’s Hospital, Seattle, Washington, USA

    Daniel J. Ledbetter

  2. Academic Pediatric Surgery Unit, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom

    Paul R.V. Johnson

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Holmes, K. (2018). Neuroblastoma. In: Ledbetter, D., Johnson, P. (eds) Endocrine Surgery in Children. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54256-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54256-9_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54254-5

  • Online ISBN: 978-3-662-54256-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation